Retrieve available abstracts of 63 articles: HTML format
Single Articles
June 2025
LIU WM, Chen CY, Ma HQ, Zhang QQ, et al Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and
nicotinic acid originating from liver progenitor cells.
J Gastroenterol. 2025;60:754-769. PubMedAbstract available
May 2025
ONO A, Hayes CN, Miura R, Kawaoka T, et al Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular
carcinoma.
J Gastroenterol. 2025 May 30. doi: 10.1007/s00535-025-02251. PubMedAbstract available
DING H, Lv H, Sui M, Wang X, et al Interaction of neuropilin-1 and hepatocyte growth factor/C-Met pathway in liver
fibrosis progression in hepatocyte-specific NRP-1 knockout mice.
J Gastroenterol. 2025 May 26. doi: 10.1007/s00535-025-02262. PubMedAbstract available
XIA M, Lu Y, Yin F, Cao Z, et al The external validation of Dallas Steatosis Index among Asian population: a
useful tool for metabolic dysfunction-associated steatotic liver disease
identification and prevention.
J Gastroenterol. 2025;60:621-631. PubMedAbstract available
April 2025
ZHANG Y, Che N, Wang S, Meng J, et al Correction: Nrf2/ASPM axis regulated vasculogenic mimicry formation in
hepatocellular carcinoma under hypoxia.
J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02246. PubMed
OURA K, Morishita A, Yano R, Manabe T, et al Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to
atezolizumab plus bevacizumab in hepatocellular carcinoma.
J Gastroenterol. 2025 Apr 3. doi: 10.1007/s00535-025-02239. PubMedAbstract available
HANAMATSU H, Suda G, Ohara M, Ogawa K, et al Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis
in patients with MASLD.
J Gastroenterol. 2025;60:456-468. PubMedAbstract available
March 2025
MIWA T, Tsuruoka M, Ueda H, Abe T, et al Current management and future perspectives of covert hepatic encephalopathy in
Japan: a nationwide survey.
J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02232. PubMedAbstract available
AOKI T, Kudo M, Nishida N, Ueshima K, et al Proposal of discontinuation criteria of atezolizumab plus bevacizumab after
curative conversion therapy for unresectable early-to-intermediate-stage
hepatocellular carcinoma: a multicenter proof-of-concept study.
J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02233. PubMedAbstract available
DU T, Huang Y, Lv Y, Yuan G, et al Liver fibrotic burden across the spectrum of hypothyroidism.
J Gastroenterol. 2025;60:315-327. PubMedAbstract available
WANG H, Liu Z, Fan H, Guo C, et al Association between advanced fibrosis and epigenetic age acceleration among
individuals with MASLD.
J Gastroenterol. 2025;60:306-314. PubMedAbstract available
February 2025
NISHIMURA T, Tada T, Akita T, Kondo R, et al Diagnostic performance of attenuation imaging versus controlled attenuation
parameter for hepatic steatosis with MRI-based proton density fat fraction as the
reference standard: a prospective multicenter study.
J Gastroenterol. 2025 Feb 24. doi: 10.1007/s00535-025-02224. PubMedAbstract available
TANAKA A, Notohara K, Tobari M, Abe M, et al A clinicopathological study of IgG4-related autoimmune hepatitis and
IgG4-hepatopathy.
J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221. PubMedAbstract available
KOGISO T, Ogasawara Y, Taniai M, Shimada E, et al Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease.
J Gastroenterol. 2025;60:210-221. PubMedAbstract available
KURODA H, Abe T, Kamiyama N, Oguri T, et al Novel subharmonic-aided pressure estimation for identifying high-risk
esophagogastric varices.
J Gastroenterol. 2025;60:187-196. PubMedAbstract available
January 2025
WEN C, Tao H, Chen H, Pu W, et al Single-cell RNA sequencing and functional analysis reveal the role of altered
glycosylation levels of hepatic macrophages in liver cirrhosis.
J Gastroenterol. 2025 Jan 31. doi: 10.1007/s00535-025-02218. PubMedAbstract available
ZHANG X, Li J, Yao Y, Zhou M, et al Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates
and metabolic disturbances in hepatocellular carcinoma.
J Gastroenterol. 2025 Jan 12. doi: 10.1007/s00535-025-02212. PubMedAbstract available
KASAI Y, Ito T, Masui T, Nagai K, et al Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis:
optimal patient selection and perioperative management in the era of multimodal
treatments.
J Gastroenterol. 2025;60:1-9. PubMedAbstract available
December 2024
ZHANG F, Wang YS, Li SP, Zhao B, et al Alpha-fetoprotein combined with initial tumor shape irregularity in predicting
the survival of patients with advanced hepatocellular carcinoma treated with
immune-checkpoint inhibitors: a retrospective multi-center cohort study.
J Gastroenterol. 2024 Dec 23. doi: 10.1007/s00535-024-02202. PubMedAbstract available
MIURA R, Ono A, Nakahara H, Shirane Y, et al Serum IL-6 concentration is a useful biomarker to predict the efficacy of
atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185. PubMedAbstract available
KAMADA Y, Sumida Y, Takahashi H, Fujii H, et al Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker
for the prediction of liver fibrosis, activity, and hepatocellular carcinoma
onset: an expert review.
J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02179. PubMedAbstract available
IMAI Y, Koizumi Y, Hiasa Y, Hirooka M, et al Standard technique in Japan for measuring hepatic venous pressure gradient.
J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02182. PubMedAbstract available
RABIU L, Zhang P, Afolabi LO, Saliu MA, et al Immunological dynamics in MASH: from landscape analysis to therapeutic
intervention.
J Gastroenterol. 2024;59:1053-1078. PubMedAbstract available
November 2024
CAO Z, Yang Y, Liu S, Sun L, et al FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic
cholangiocarcinoma.
J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175. PubMedAbstract available
October 2024
LIU WJ, Wu WJ, Lin CL, Liu CJ, et al Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in
men with chronic HBV infection based on multi-state modeling of the natural
history.
J Gastroenterol. 2024 Oct 22. doi: 10.1007/s00535-024-02162. PubMedAbstract available
UENO M, Takeda H, Takai A, Morimura H, et al Publisher Correction: CRAFITY score as a predictive marker for refractoriness to
atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter
retrospective study.
J Gastroenterol. 2024 Oct 21. doi: 10.1007/s00535-024-02159. PubMed
SOMA N, Uchida Y, Kouyama JI, Naiki K, et al Serum zinc levels as predictors of covert hepatic encephalopathy in patients with
liver cirrhosis.
J Gastroenterol. 2024 Oct 16. doi: 10.1007/s00535-024-02160. PubMedAbstract available
KAWAGUCHI T, Fujishima Y, Wakasugi D, Io F, et al Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic
cancer in type 2 diabetic patients with suspected MASLD: a nationwide database
study in Japan.
J Gastroenterol. 2024 Oct 11. doi: 10.1007/s00535-024-02158. PubMedAbstract available
HANAI T, Nishimura K, Unome S, Miwa T, et al Response to letter to the editor regarding: "Alcohol-associated liver disease
increases the risk of muscle reduction and mortality in patients with cirrhosis".
J Gastroenterol. 2024 Oct 4. doi: 10.1007/s00535-024-02153. PubMed
SANCHEZ-MONTEAGUDO A, Ripolles E, Murillo O, Domenech S, et al Profile of plasma microRNAs as a potential biomarker of Wilson's disease.
J Gastroenterol. 2024;59:921-931. PubMedAbstract available
September 2024
KUNZLER IL, Da Croce MA, Fornari F Alcohol-associated liver disease increases the risk of muscle loss and mortality
in patients with cirrhosis.
J Gastroenterol. 2024 Sep 23. doi: 10.1007/s00535-024-02154. PubMed
UENO M, Takeda H, Takai A, Morimura H, et al CRAFITY score as a predictive marker for refractoriness to atezolizumab plus
bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective
study.
J Gastroenterol. 2024 Sep 18. doi: 10.1007/s00535-024-02150. PubMedAbstract available
YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al Single-molecule sequencing of the whole HCV genome revealed envelope deletions in
decompensated cirrhosis associated with NS2 and NS5A mutations.
J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146. PubMedAbstract available
KAWAGUCHI T, Murotani K, Kajiyama H, Obara H, et al Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled
meta-analysis of phase III clinical trials.
J Gastroenterol. 2024;59:836-848. PubMedAbstract available
August 2024
YU C, Tang Y, Liu M, Xu X, et al The risk stratification and predictive performance of a new combined polygenic
risk score for hepatocellular carcinoma.
J Gastroenterol. 2024 Aug 10. doi: 10.1007/s00535-024-02144. PubMedAbstract available
ZHANG Y, Che N, Wang S, Meng J, et al Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular
carcinoma under hypoxia.
J Gastroenterol. 2024 Aug 3. doi: 10.1007/s00535-024-02140. PubMedAbstract available
July 2024
HANAI T, Nishimura K, Unome S, Miwa T, et al Alcohol-associated liver disease increases the risk of muscle loss and mortality
in patients with cirrhosis.
J Gastroenterol. 2024 Jul 28. doi: 10.1007/s00535-024-02137. PubMedAbstract available
HAO Y, Hao Z, Zeng X, Lin Y, et al Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target
on the therapeutic regulation.
J Gastroenterol. 2024 Jul 19. doi: 10.1007/s00535-024-02134. PubMedAbstract available
AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al The biochemical pattern defines MASLD phenotypes linked to distinct histology and
prognosis.
J Gastroenterol. 2024;59:586-597. PubMedAbstract available
June 2024
MIWA T, Utakata Y, Hanai T, Aiba M, et al Acute kidney injury development is associated with mortality in Japanese patients
with cirrhosis: impact of amino acid imbalance.
J Gastroenterol. 2024 Jun 11. doi: 10.1007/s00535-024-02126. PubMedAbstract available
WAKABAYASHI SI, Tamaki N, Kimura T, Umemura T, et al Natural history of lean and non-lean metabolic dysfunction-associated steatotic
liver disease.
J Gastroenterol. 2024;59:494-503. PubMedAbstract available
HIROOKA M, Ogawa S, Koizumi Y, Yoshida Y, et al iATT liver fat quantification for steatosis grading by referring to MRI proton
density fat fraction: a multicenter study.
J Gastroenterol. 2024;59:504-514. PubMedAbstract available
MINO M, Sano A, Kakazu E, Matsubara H, et al Differences in branched-chain amino acid to tyrosine ratio (BTR) among etiologies
of chronic liver disease progression compared to healthy adults.
J Gastroenterol. 2024;59:483-493. PubMedAbstract available
May 2024
ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al ALBI score predicts morphological changes in esophageal varices following
direct-acting antiviral-induced sustained virological response in patients with
liver cirrhosis.
J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109. PubMedAbstract available
April 2024
FUJIWARA K, Kondo T, Fujimoto K, Yumita S, et al Clinical risk factors for portal hypertension-related complications in systemic
therapy for hepatocellular carcinoma.
J Gastroenterol. 2024 Apr 7. doi: 10.1007/s00535-024-02097. PubMedAbstract available
CORNEJO-PAREJA I, Amiar MR, Ocana-Wilhelmi L, Soler-Humanes R, et al Non-alcoholic fatty liver disease in patients with morbid obesity: the gut
microbiota axis as a potential pathophysiology mechanism.
J Gastroenterol. 2024;59:329-341. PubMedAbstract available
March 2024
XIN HY, Zou JX, Sun RQ, Hu ZQ, et al Characterization of tumor microbiome and associations with prognosis in
intrahepatic cholangiocarcinoma.
J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090. PubMedAbstract available
WANG J, Zhang H, Chen L, Fu K, et al CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating
STUB1-mediated PARK7 ubiquitination degradation.
J Gastroenterol. 2024;59:229-249. PubMedAbstract available
February 2024
WU C, Li J, Jia H, Zhao J, et al Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes
to lipid deposition in nonalcoholic steatohepatitis.
J Gastroenterol. 2024 Feb 24. doi: 10.1007/s00535-024-02082. PubMedAbstract available
NAMISAKI T, Sato S, Yoshiji H Role of combined aerobic and resistance exercise in liver cirrhosis.
J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078. PubMed
January 2024
KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al Prediction of outcomes in patients with metabolic dysfunction-associated
steatotic liver disease based on initial measurements and subsequent changes in
magnetic resonance elastography.
J Gastroenterol. 2024;59:56-65. PubMedAbstract available
HANAI T, Nishimura K, Unome S, Miwa T, et al A survey questionnaire evaluating physical activity patterns and determinants in
patients with chronic liver disease.
J Gastroenterol. 2024;59:45-55. PubMedAbstract available
December 2023
KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al Resistance exercise in combination with aerobic exercise reduces the incidence of
serious events in patients with liver cirrhosis: a meta-analysis of randomized
controlled trials.
J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060. PubMedAbstract available
ICHITA C, Goto T, Shimizu S Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with
upper gastrointestinal bleeding in real-world data.
J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066. PubMed
UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic
patients with upper gastrointestinal bleeding in real-world data".
J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067. PubMed
November 2023
YANG Z, Shi M, Liang Y, Zhang F, et al Three-dimensional chromatin landscapes in hepatocellular carcinoma associated
with hepatitis B virus.
J Gastroenterol. 2023 Nov 5. doi: 10.1007/s00535-023-02053. PubMedAbstract available
October 2023
WANG H, Li Y, Pu X, Liang X, et al MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic
acid-treated patients with primary biliary cholangitis.
J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045. PubMedAbstract available
TAHATA Y, Hikita H, Mochida S, Enomoto N, et al Posttreatment liver function, but not baseline liver function stratifies patient
survival after direct-acting antiviral treatment in decompensated cirrhosis with
hepatitis C virus.
J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039. PubMedAbstract available
CRANE H, Gofton C, Sharma A, George J, et al MAFLD: an optimal framework for understanding liver cancer phenotypes.
J Gastroenterol. 2023;58:947-964. PubMedAbstract available
September 2023
KADO A, Tsutsumi T, Yotsuyanagi H, Ikeuchi K, et al Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis
overlapping autoimmune hepatitis based on peripheral lymphocyte pattern.
J Gastroenterol. 2023 Sep 14. doi: 10.1007/s00535-023-02038. PubMedAbstract available
WEI M, Chen Y, Wang M, Li J, et al Correction: Partial splenic embolization combined with endoscopic therapies and
vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute
variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036. PubMed
OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al Current status and issues in genomic analysis using EUS-FNA/FNB specimens in
hepatobiliary-pancreatic cancers.
J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037. PubMedAbstract available
LIU C, Zhu S, Zhang J, Wu P, et al Global, regional, and national burden of liver cancer due to non-alcoholic
steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis.
J Gastroenterol. 2023 Sep 4. doi: 10.1007/s00535-023-02040. PubMedAbstract available